Imprime PGG

BIOLOGICAL10 trials

Sponsors

HiberCell, Inc., Dana-Farber Cancer Institute, University of Illinois at Chicago, Lawrence Feldman, MD, Hoffmann-La Roche

Conditions

Advanced MelanomaColorectal CancerHealthyMalignant Neoplasm of BreastNon-Small Cell Lung CancerPancreatic CancerPathologic Stage III Cutaneous Melanoma AJCC v8Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas

Phase 1

Phase Ia Dose-Escalation Safety, Pharmacodynamic and Pharmacokinetic Study of Imprime PGG™ Injection

CompletedNCT00542217

HiberCell, Inc.Healthy

Start: 2005-12-31End: 2006-04-30Updated: 2007-10-11

(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer

TerminatedNCT02132403

University of Illinois at ChicagoPancreatic Cancer

Start: 2014-08-31End: 2015-04-30Updated: 2015-05-01

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

CompletedNCT03003468

Lawrence Feldman, MDNon-Small Cell Lung Cancer

Start: 2017-07-11End: 2022-11-28Updated: 2026-01-20

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

TerminatedNCT03555149

Hoffmann-La RocheColorectal Cancer

Start: 2018-09-27End: 2022-09-26Updated: 2023-11-07

Phase 2

A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

CompletedNCT02086175

Dana-Farber Cancer InstituteRelapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas

Start: 2014-12-31End: 2021-02-01Updated: 2024-04-09

Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer

CompletedNCT02981303

HiberCell, Inc.Advanced Melanoma, Triple-Negative Breast Cancer

Start: 2017-02-22End: 2020-12-31Updated: 2024-07-09

Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD

TerminatedNCT03246685

HiberCell, Inc.Squamous Cell Carcinoma of the Head and Neck

Start: 2017-11-08End: 2018-04-13Updated: 2018-12-14

Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma

WithdrawnNCT04995094

HiberCell, Inc.Pathologic Stage III Cutaneous Melanoma AJCC v8

Start: 2021-08-15End: 2023-05-18Updated: 2021-11-05

Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

CompletedNCT05159778

HiberCell, Inc.Malignant Neoplasm of Breast

Start: 2021-11-09End: 2023-04-12Updated: 2023-06-22

Unknown Phase

Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer

CompletedNCT00912327

HiberCell, Inc.Colorectal Cancer

Start: 2009-06-30End: 2012-02-29Updated: 2012-02-15

Related Papers

Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapy

The Journal of Immunology2025-05-081 citations

Abstract CT169: Phase Ib/II open-label, randomized study of atezolizumab + regorafenib + AB928 or atezolizumab + regorafenib vs regorafenib for patients with microsatellite-stable, refractory metastatic colorectal cancer in MORPHEUS-CRC

Cancer Research2025-04-25

Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017.

2024-11-191 citations

Abstract B086: Novel myeloid activation therapy promotes regression of metastatic ovarian cancer

Cancer Research2024-03-04

Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer

Communications Medicine2022-07-1518 citations

A multicenter, open-label, phase 2 study of odetiglucan (IMPRIME PGG) and pembrolizumab in patients with metastatic breast cancer (mBCA) who have progressed through prior hormonal therapy.

Journal of Clinical Oncology2022-06-011 citations

Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + Imprime PGG (Imprime) + bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2021-05-202 citations

Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer.

Journal of Clinical Oncology2021-01-203 citations

259 Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC

Regular and Young Investigator Award Abstracts2020-11-012 citations

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Cancer Research2020-08-159 citations

P862 Clinical benefit potentially evident with immunopharmacodynamic responses in prior-checkpoint failed metastatic melanoma patients treated with imprime PGG and pembrolizumab

Poster presentations2020-04-012 citations

P859 Association of immunopharmacodynamic responses of imprime PGG plus pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects failing front-line chemotherapy

Poster presentations2020-04-011 citations

Abstract PD1-02: Response and clinical benefit assessment of the combination of the dectin-1 agonist imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

Cancer Research2020-02-158 citations

A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND β‐GLUCAN PGG IN RELAPSED/REFRACTORY INDOLENT B‐CELL NON‐HODGKIN LYMPHOMA

Hematological Oncology2019-06-013 citations

An open label, multicenter phase II study combining imprime PGG (PGG) with pembrolizumab (<i>P</i>) in previously treated metastatic triple-negative breast cancer (mTNBC).

Journal of Clinical Oncology2019-05-209 citations

MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers.

Journal of Clinical Oncology2019-01-2914 citations

A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer

Journal for ImmunoTherapy of Cancer2018-02-2721 citations

Abstract OT1-01-04: A phase 2, open-label study of imprime PGG (Imprime), a novel beta glucan, with pembrolizumab (Pembro) in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

Cancer Research2018-02-153 citations

A multicenter, open-label, phase II study of PGG beta-glucan and pembrolizumab in patients (pts) with advanced melanoma (MEL) following progression on treatment with checkpoint inhibitors (CPI) or triple negative breast cancer (TNBC) failing front-line chemotherapy for metastatic disease.

Journal of Clinical Oncology2017-05-202 citations

A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.

2017-03-1637 citations

1 more papers not shown